Beam Therapeutics BEAM
NASDAQ BEAM
$24.52 +0.29 (+1.20%)
At close: Sep 29, 2026 · 4:00 PM EDT

Beam Therapeutics (BEAM) Debt Ratio (2026)

Updated

Beam Therapeutics' Debt Ratio came in at 0.07 for Q2 2026, up 6.9% from the prior quarter.

Analysis

Beam Therapeutics (BEAM) Debt Ratio (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 0.24
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 0.52
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 0.42
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 0.31
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 0.00
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 0.60
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Beam Therapeutics 2.50 Bn 2.50 Bn - 0.07
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.07
Mar 31, 2026 0.07
API Access

Beam Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=BEAM&period=max&api_key=YOUR_API_KEY